在未接受过生物制剂改善病情抗风湿药的活动性银屑病关节炎患者中,依奇珠单抗联合或不联合传统改善病情抗风湿药的疗效与安全性:SPIRIT-P1研究结果
SPIRIT-P1亚组分析按是否联用传统改善病情抗风湿药(cDMARDs)分层,评估依奇珠单抗80mg每4周或每2周与安慰剂相比在活动性银屑病关节炎(PsA)患者中的疗效与安全性。无论是否联用cDMARDs,依奇珠单抗两个给药方案第24周的ACR20/50/70应答率均显著高于安慰剂;治疗中出现的不良事件较安慰剂更频繁,严重不良事件未高于安慰剂。
要点
- 无论是否联用cDMARDs,依奇珠单抗每4周或每2周方案的ACR20/50/70应答率均显著高于安慰剂。
- 联用cDMARDs时每4周方案及无论是否联用cDMARDs时每2周方案,达到HAQ-DI最小临床重要差异的患者比例显著高于安慰剂。
- 无论是否联用cDMARDs,依奇珠单抗两个方案的治疗中出现的不良事件均较安慰剂更频繁,严重不良事件未高于安慰剂。
核心结论
- 依奇珠单抗联合或不联合cDMARD治疗,均较安慰剂改善活动性PsA患者的疾病活动度指标和躯体功能。
研究设计与样本
- SPIRIT-P1亚组分析(NCT01695239),患者按cDMARD使用情况分层后随机分配至依奇珠单抗80mg每4周、每2周或安慰剂组。
主要发现
- 无论是否联用cDMARDs,依奇珠单抗每4周和每2周方案第24周的ACR20、ACR50、ACR70应答率均显著高于安慰剂。
- 联用cDMARDs时依奇珠单抗每4周方案及无论是否联用cDMARDs时每2周方案,达到HAQ-DI最小临床重要差异的患者比例显著高于安慰剂。
- 无论是否联用cDMARDs,依奇珠单抗两个方案的治疗中出现的不良事件均较安慰剂更频繁,严重不良事件未高于安慰剂。
关键数值与推荐
- 疗效评估指标包括美国风湿病学会标准(ACR20/50/70)、改良总Sharp评分和健康评估问卷-残疾指数(HAQ-DI),评估时间点为第24周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239). METHODS: Patients were stratified by cDMARD use (concomitant cDMARDs use (including methotrexate) or none (past or naïve use)) and randomly assigned to treatment groups (ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) or placebo). Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50/70), modified total Sharp score and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed according to cDMARD status. RESULTS: Regardless of concomitant cDMARD usage, ACR20, ACR50 and ACR70 response rates were significantly higher versus placebo with IXEQ4W and IXEQ2W. The proportion of patients achieving HAQ-DI minimal clinically important difference was significantly higher versus placebo with IXEQ4W with concomitant cDMARD use and IXEQ2W, regardless of concomitant cDMARD use. Treatment-emergent adverse events (AE) were more frequent versus placebo for either ixekizumab-dosing regimen, regardless of concomitant cDMARD use. Serious AEs were not higher versus placebo, regardless of concomitant cDMARD use. CONCLUSION: Ixekizumab treatment improved measures of disease activity and physical function in patients with active PsA relative to placebo, when used with or without concomitant cDMARD therapy.
引用
- Coates LC, Kishimoto M, Gottlieb A, et al. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. RMD Open. 2017. PMID: 29299340. doi:10.1136/rmdopen-2017-000567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。